SCHEMBL365645

SCHEMBL365645

COc1ccc(COc2ccc(C(=O)NS(C)(=O)=O)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.70
MAPT P10636 2/20 0.70
HTT P42858 1/20 0.70
NPC1 O15118 3/20 0.62
RAB9A P51151 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
POLB P06746 1/20 0.62
FFAR1 O14842 2/20 0.56
PTGER4 P35408 1/20 0.56
PLA2G4B P0C869 1/20 0.56
SMPD1 P17405 1/20 0.55
MAPK1 P28482 1/20 0.55
ADAM17 P78536 1/20 0.54
GFER P55789 1/20 0.52
BCL2L1 Q07817 1/20 0.52
MCL1 Q07820 1/20 0.52
SCN9A Q15858 1/20 0.52
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16239768 1.00 ALDH1A1 (0.70) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL364340 0.89 RXRA (0.62) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL365210 0.88 MAOA (0.63) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL366081 0.88 MAOA (0.63) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL366812 0.88 MAOB (0.63) ALDH1A1MAPTHTTMAPK1ADAM17
SCHEMBL365173 0.87 MAOB (0.61) ALDH1A1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL364835 0.87 SMPD1 (0.60) ALDH1A1MAPTHTTPOLBSMPD1
SCHEMBL7985093 0.87 CA1 (0.67) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL366713 0.86 RAB9A (0.57) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL366501 0.85 RAB9A (0.62) ALDH1A1MAPTHTTRAB9ASMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A ALDH1A1 767/4885MAPT 3262/4885HTT 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.